Epidermal growth factor (EGF) fragment-guided anticancer theranostic particles for pH-responsive release of doxorubicin
Publication date: 15 March 2017 Source:International Journal of Pharmaceutics, Volume 519, Issues 1–2 Author(s): Myun Koo Kang, Wei Mao, Jun Bae Lee, Hyuk Sang Yoo EGF fragment (EGFfr) and doxorubicin were chemically co-decorated on single magnetic nanoparticles (MNPs) for concomitant cancer targeting and treatment. Magnetic nanoparticles were prepared by the precipitation of ferric chloride hydrates in an ammonia solution and subsequent surface-functionalization with amines. The terminal thiol group of the EGF fragment was first conjugated to surface amines of the MNPs using a heterofunctional crosslinker, and doxorubicin was sequentially conjugated to the MNPs via a hydrazone linker, where the degree of subsitution of the surface amines to EGFfr was varied from 1% to 40%. The decorated doxorubicin showed clear pH-dependency in the release profile, and doxorubicin showed fast release at pH 5.0 in comparison to pH 7.4. The EGF-decorated MNPs were tested for differential cellular uptakes against EGF overexpressing cells (A549), and the uptake levels gradually increased to 10% and saturated, which was quantified by ICP-OES. Internalized doxorubicin was also visualized by confocal microscopy, and A549 cells with EGF-decorated MNPs with EGF decoration showed higher fluorescence intensity of doxorubicin than those with non-decorated MNPs. Anti-cancer activity of the MNPs was compared at various concentrations of doxorubicin and EGFfr. Decoration of EGFfr significantly incre...
Conclusion: If otologic manifestations such as facial palsy and hearing loss are presented in patients at advanced stages of malignancy, TBM of primary malignancy should be suspected. In addition, hematologic malignancies tend to metastasize to the external auditory canal and the middle ear cleft more commonly than solid cancers do. PMID: 29909612 [PubMed - as supplied by publisher]
Juan-Juan Gao, Yang Zhang, Markus Gerhard, Raquel Mejias-Luque, Lian Zhang, Michael Vieth, Jun-Ling Ma, Monther Bajbouj, Stepan Suchanek, Wei-Dong Liu, Kurt Ulm, Michael Quante, Zhe-Xuan Li, Tong Zhou, Roland Schmid, Meinhard Classen, Wen-Qing Li, Wei-Cheng You, Kai-Feng Pan
African Americans and Latinos with recent-onset diabetes have a much higher risk of developing pancreatic cancer than their counterparts without diabetes.Medscape Medical News
Seyeon Park, Seunghyun Ahn, Yujeong Shin, Yoonjung Yang, Chang H. Yeom
BREAST cancer symptoms begin to appear when cells grow and divide uncontrollably in this area. You should check your whole breast regularly for any warning sign of breast cancer. Watch out for these three signs of the condition.
ZURICH/LONDON (Reuters) - Swiss drugmaker Roche is paying $2.4 billion to buy the rest of Foundation Medicine (FMI) , raising its bet on the U.S. genomic profiling group's ability to personalize cancer care.
This review highlights evidence from recent practice-changing clinical trials on new approaches to sentinel lymph node biopsy and axillary lymph node dissection in breast cancer patients.American Journal of Clinical Pathology
By CHARLES SILVER and DAVID A.HYMAN Today THCB is happy to publish a piece reflecting the learnings from Charles Silver and David Hyman’s forthcoming book Overcharged: Why Americans Pay Too Much For Health Care, shortly to be published by the libertarian leaning Cato Institute. In subsequent weeks we’ll feature commentary from the right (Michael Cannon) and from the left (Andy Slavitt) about the book and its proposals. For now please give your views in the comments–Matthew Holt There are many reasons why the United States is “the most expensive place in the world to get sick.” In Par...
CONCLUSIONS The present study reveals that in ovarian cancer cells, prucalopride inhibits proliferation, migration, and invasion, and induces apoptosis and autophagy, which may be regulated by the PI3K signaling pathway. These results suggest prucalopride has potential as a new drug for clinical ovarian cancer treatment. PMID: 29909423 [PubMed - in process]
CONCLUSIONS TCF21 is downregulated in ESCC, and its low expression is closely correlated with N stage and predicts a poor prognosis. TCF21 functions as a tumor suppressor in ESCC progression, and enhancement of its expression levels may be partly through promoting Kiss-1 expression to reverse EMT by modulating EMT-related gene expression. Thus, TCF21 can potentially be used as a treatment target for ESCC. PMID: 29909422 [PubMed - in process]